Advaxis, Inc.
(NASDAQ : ADXS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen, Inc. -0.15%247.721.3%$844.18m
MRNAModerna, Inc. 2.92%69.870.0%$763.28m
NVAXNovavax, Inc. -6.19%108.3696.5%$693.95m
IMMUImmunomedics, Inc. 0.22%85.5311.0%$600.97m
GILDGilead Sciences, Inc. 0.02%65.051.0%$599.14m
REGNRegeneron Pharmaceuticals, Inc. -1.73%555.242.7%$445.10m
BIIBBiogen, Inc. -0.32%274.481.6%$332.97m
VRTXVertex Pharmaceuticals, Inc. -2.24%265.391.9%$329.17m
ILMNIllumina, Inc. -0.85%295.503.5%$313.09m
SRNESorrento Therapeutics, Inc. -0.53%9.431.5%$274.82m
ALXNAlexion Pharmaceuticals, Inc. -0.36%113.722.0%$266.55m
BMRNBioMarin Pharmaceutical, Inc. 1.30%79.384.3%$239.49m
MNTAMomenta Pharmaceuticals, Inc. -0.13%52.263.0%$237.34m
VXRTVaxart, Inc. 3.01%8.220.0%$213.57m
SGENSeattle Genetics, Inc. 3.01%180.946.0%$194.15m

Company Profile

Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. It has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ.